Get the Stockscreener App
4.39
6.20%
-0.29
After Hours:
4.39
Camp 4 Therapeutics Corp stock is traded at $4.39, with a volume of 34,804.
It is down -6.20% in the last 24 hours and down -27.32% over the past month.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$4.68
Open:
$4.8
24h Volume:
34,804
Relative Volume:
0.22
Market Cap:
$227.76M
Revenue:
$264.74M
Net Income/Loss:
$-49.71M
P/E Ratio:
-1.0718
EPS:
-4.0959
Net Cash Flow:
$-43.55M
1W Performance:
+22.28%
1M Performance:
-27.32%
6M Performance:
+218.12%
1Y Performance:
-1.79%
1-Day Range:
$4.39
$4.80
1-Week Range:
$3.585
$4.8486
52-Week Range:
$1.305
$7.305
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.39 | 242.80M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-16-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-27-25 | Initiated | Wedbush | Outperform |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
FMR LLC Increases Stake in Camp4 Therapeutics Corp: A Strategic Move in Biotechnology - GuruFocus
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
Downgrade Watch: Can Camp4 Therapeutics Corporation ride the EV waveTrade Analysis Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Will Camp4 Therapeutics Corporation benefit from rising consumer demand2025 Sector Review & Verified Momentum Stock Alerts - mfd.ru
Analysis Recap: Will Camp4 Therapeutics Corporation outperform the market in YEAR2025 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Retail Trends: Is CVD Equipment Corporation stock undervalued right nowExit Point & Low Volatility Stock Recommendations - baoquankhu1.vn
Market Outlook: Will Camp4 Therapeutics Corporation stock benefit from M AJuly 2025 Final Week & Growth Focused Stock Pick Reports - baoquankhu1.vn
CAMP4 Therapeutics announces $28 million common stock offering - MSN
Signal Recap: Will Camp4 Therapeutics Corporation outperform the market in YEARMarket Growth Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
New CAMP4 hire receives option to buy 8,000 shares at $5.78 each in grant - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why - sharewise.com
Published on: 2026-01-10 23:34:38 - ulpravda.ru
CAMP4 Therapeutics updates corporate investor presentation materials - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Scrip Asks... What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking - Citeline News & Insights
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail
Stock Recap: What hedge fund activity signals for Camp4 Therapeutics Corporation stockMarket Performance Report & Verified Technical Signals - Улправда
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Wedbush Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation - MSN
Insilico’s big gain after Hong Kong listing: Finance Report - biocentury.com
Sanofi adds HBV vaccine, shingles candidate via Dynavax takeout: Deals Report - BioCentury
Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER) - The Globe and Mail
Camp4 Therapeutics signs new Watertown lease, accelerates Cambridge exit By Investing.com - Investing.com South Africa
Camp4 Therapeutics signs new Watertown lease, accelerates Cambridge exit - Investing.com
CAMP4 Therapeutics Restructures Leases and Expands Facilities - TipRanks
Deal Watch: Boehringer Signs On For Rectify’s Chronic Kidney Disease Assets - Citeline News & Insights
Is Camp4 Therapeutics Corporation a good long term investmentMarket Timing Techniques & Superior Capital Trading - earlytimes.in
Will Camp4 Therapeutics Corporation stock benefit from green energy trends2025 Technical Overview & Real-Time Buy Signal Notifications - Улправда
How Camp4 Therapeutics Corporation stock valuations compare to rivals2025 Sector Review & Real-Time Volume Triggers - Улправда
Market Rankings: How Camp4 Therapeutics Corporation stock performs in rate cut cyclesWeekly Trade Recap & Community Trade Idea Sharing - Улправда
Will Camp4 Therapeutics Corporation stock deliver better than expected guidanceTrade Entry Report & Long-Term Safe Investment Ideas - Улправда
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Benzinga
Quarterly Recap: Will Camp4 Therapeutics Corporation stock outperform international peersJuly 2025 Chart Watch & Detailed Earnings Play Alerts - Улправда
How Camp4 Therapeutics Corporation stock performs in rate cut cyclesJuly 2025 Update & Weekly High Momentum Picks - Улправда
CAMP4 Therapeutics (Nasdaq:CAMP) Enters Research and License Agreement with GSK - Kalkine Media
CAMP4 Therapeutics Announces $28 Million Common Stock Offering - TipRanks
CAMP4 Therapeutics (CAMP) to raise about $28M in 5M-share equity deal - Stock Titan
Will Camp4 Therapeutics Corporation stock outperform international peersGap Down & Advanced Technical Analysis Signals - Улправда
CAMP4 Therapeutics and GSK partner on ASO development for diseases By Investing.com - Investing.com Nigeria
CAMP4 Therapeutics prices $30 million common stock offering By Investing.com - Investing.com Nigeria
CAMP4 and GSK enter strategic collaboration to advance RNA-based therapeutic discoveries - PharmaLive
CAMP4, GSK form RNA therapeutics collaboration agreement - TipRanks
CAMP4 Therapeutics prices $30 million common stock offering - Investing.com India
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock - The Manila Times
CAMP4 Therapeutics and GSK partner on ASO development for diseases - Investing.com
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):